Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Mar 16;26(6):1659.
doi: 10.3390/molecules26061659.

Obesity and Energy Substrate Transporters in Ovarian Cancer-Review

Marta Baczewska  1 , Klaudia Bojczuk  1 , Adrian Kołakowski  1 , Jakub Dobroch  1 , Paweł Guzik  2 , Paweł Knapp  1   3
Affiliations
Review

Obesity and Energy Substrate Transporters in Ovarian Cancer-Review

Marta Baczewska et al. Molecules. .

Abstract

Ovarian cancer is the seventh most common cancer in women. It is characterized by a high mortality rate because of its aggressiveness and advanced stage at the time of diagnosis. It is a nonhomogenous group of neoplasms and, of which the molecular basics are still being investigated. Nowadays, the golden standard in the treatment is debulking cytoreductive surgery combined with platinum-based chemotherapy. We have presented the interactions and the resulting perspectives between fatty acid transporters, glucose transporters and ovarian cancer cells. Studies have shown the association between a lipid-rich environment and cancer progression, which suggests the use of correspondent transporter inhibitors as promising chemotherapeutic agents. This review summarizes preclinical and clinical studies highlighting the role of fatty acid transport proteins and glucose transporters in development, growth, metastasizing and its potential use in targeted therapies of ovarian cancer.

Keywords: cancer progression; lipids; obesity; ovarian cancer; targeted therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
High-grade ovarian cancer‚ omental cake-like metastasis to the omentum in a 68-year old female; FIGO IIIC; 2019. University Oncology Center, Bialystok, Poland.
Figure 2
Figure 2
Proposed model of FABP4 role in the ovarian cancer cell [75,78] by Baczewska et al. SU6656—SRC-inhibitor; L.D—lipid droplets; FFA—free fatty acids; HSL—hormone-sensitive lipase.
See this image and copyright information in PMC

References

    1. Lheureux S., Braunstein M., Oza A.M. Epithelial ovarian cancer: Evolution of management in the era of precision medicine. CA Cancer J. Clin. 2019;69:280–304. doi: 10.3322/caac.21559. - DOI - PubMed
    1. Webb P.M., Jordan S.J. Epidemiology of epithelial ovarian cancer. Best Pract. Res. Clin. Obstet. Gynaecol. 2017;41:3–14. doi: 10.1016/j.bpobgyn.2016.08.006. - DOI - PubMed
    1. Torre L.A., Trabert B., DeSantis C.E., Miller K.D., Samimi G., Runowicz C.D., Gaudet M.M., Jemal A., Siegel R.L. Ovarian cancer statistics, 2018. [(accessed on 29 May 2018)];CA Cancer J. Clin. 2018 68:284–296. Available online: https://pubmed.ncbi.nlm.nih.gov/29809280. - PMC - PubMed
    1. Bosetti C., Bertuccio P., Malvezzi M., Levi F., Chatenoud L., Negri E., La Vecchia C. Cancer mortality in Europe, 2005-2009, and an overview of trends since 1980. Ann. Oncol. 2013;24:2657–2671. doi: 10.1093/annonc/mdt301. - DOI - PubMed
    1. Konstantinopoulos P.A., Ceccaldi R., Shapiro G.I., D’Andrea A.D. Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer. Cancer Discov. 2015;5:1137–1154. doi: 10.1158/2159-8290.CD-15-0714. - DOI - PMC - PubMed

MeSH terms

Substances

LinkOut - more resources